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ABStrACt 
Cancer-causing viruses are responsible for up to 20% of cancers with infectious etiology, representing a serious public health problem worldwide. 
Since the discovery of the first human cancer-causing virus, several others have been associated with neoplasias. Recent advances in technologies 
for the determination of genomic and proteomic profiles have resulted in the discovery and availability of tumor markers with potential 
application in the screening, diagnosis, prognosis and treatment of cancer. Therefore, laboratory medicine has stood out as a fundamental tool 
in the prevention and management of these diseases.
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introDuCtion
Cancer is the main cause of mortality worldwide, mostly in 
developing countries, where it is responsible for approximately a fifth 
of total deaths(27). Official estimates from the International Agency in 
Cancer Research indicate that up to 20% of total cancers are caused by 
infectious agents, mainly viruses(6). This type of cancer represents a major 
public health problem in developing countries, low income populations 
and immunosuppressed patients from developed countries(24).
Discovery of cancer-causing viruses
In 1911, Peyton Rous concluded his experiments at the Rockfeller 
Institute in the USA, in which he transplanted a sarcoma from one 
hen into others from the same brood. That was the first evidence that 
cancer could be transmitted by cell-free extracts and that it could be 
caused by a small transmitting agent, probably a virus.
Similar experiments were published by two Danish scientists, 
Vilhelm Ellerman and Oluf Bang, who proved the viral transmission 
of avian erythroblastosis(13). Notwithstanding, these evidences were 
regarded as scientific curiosities. Almost twenty years afterwards, 
new studies described the presence of virus in mammalian tumors 
in 1930(2).
The interest in the viral causes of cancer accrued in the early 
1950’s with the discovery of murine retrovirus and polyomavirus, 
which cause tumors in murines(20).  Only fifty three years after Rous’s 
first experiments, the first human tumor-causing virus was described. 
The Epstein-Barr virus (EBV), also known as human herpesvirus 4 
(HHV4), identified in 1964 by electronic microscopy of cellular 
lineages from African patients with Burkitt lymphoma(14).
Six other human cancer-causing viruses have been discovered in 
the last decades (Table), and others have been listed despite the fact 
that their role in human cancer has not been fully elucidated yet(24).
The discovery of hepatitis B virus (HBV) occurred after World War 
II when clinical and epidemiological studies started to differentiate 
several types of acute hepatitis. In 1967, Krugman et al. established 
the existence of at least two types of hepatitis, one of which presented 
parenteral transmission. It is known as serum hepatitis, currently 
called hepatitis B. Serological studies conducted by two independent 
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research groups identified an antigen in the serum of patients with 
blood-borne hepatitis, namely the HBV surface antigen (HBsAg). 
These studies enabled the serological diagnosis of hepatitis B and 
initiated several epidemiological investigations(19). The role of HBV 
in hepatocellular carcinoma was established a decade afterwards by 
means of longitudinal studies in areas of high HBV prevalence(1, 3).
In 1980, the human T lymphotropic virus type 1 was discovered 
and identified by culture and electronic microscopy of adult T cell 
lymphoma. It was the first human retrovirus described as a potential 
cause of malignity(18, 29). Some time afterwards the high risk human 
papillomaviruses ([HPV] 16 and 18) were described as the main 
causes of cervical cancer by means of hybridization of papillomavirus 
deoxyribonucleic acid (DNA). In studies that investigated the role of 
this virus in sexually transmitted genital warts, they were known as 
cervical cancer DNA(5, 12).
The causing agent of blood-borne hepatitis  continued to be 
investigated until the end of 1980’s. In 1989, Qui-Lim Choo et al. 
isolated hepatitis C virus (HCV) in serum from a patient with hepatitis 
non A non B in the USA. This virus (HCV) was immediately associated 
with hepatocellular carcinoma as well as HBV(10).
More recently, the Kaposi sarcoma herpesvirus (KSHV), also 
known as human herpesvirus 8 (HHV8) and the Merkel cell 
polyomavirus (MCV) have been discovered, both through experiments 
based on  nucleic acid extraction(9, 17).
The events from this first century of investigations into tumoral 
infections caused by virus culminated with the Nobel prizes in 2008 
for the discovery of high risk HPV strains by Harald zur Hausen 
and the discovery of the acquired immunodeficiency virus (HIV) 
by Fraçois Barré-Sinoussi and Luc Montagnier. The former are 
responsible for cervical cancer and the latter is an agent that does 
not initiate cancer, yet it indirectly fosters malignity by means of 
immunosuppression(24).
tABLE – Human cancer-causing viruses
Virus Genome Cancer Year Reference
EBV, also known as HHV4 Herpesvirus with double-stranded DNA




Hepadnavirus with partially  
double-stranded DNA
Hepatocellular carcinoma 1965 4
HTLV-1 Retrovirus with single-stranded RNA Adult T cell leukemia 1980 29
HPV 16 and 18 Papillomavirus with double-stranded DNA Cervical and penile cancer 1983-1984 5, 12
HCV Flavivirus with single-stranded RNA Hepatocellular carcinoma 1989 10
KSHV, also known as HHV8 Herpesvirus with double-stranded DNA Kaposi sarcoma 1994 9
 MCV Polyomavirus with double-stranded DNA Merkel cell carcinoma 2008 17
Adapted from Moore and Chang (2011)(24).
EBV:  Epstein-Barr virus; HHV4: human herpesvirus 4; DNA: deoxyribonucleic acid; HBV: hepatitis B virus; HTLV-1: human T lymphotropic virus type 1; RNA: 
ribonucleic acid; HPV: human papillomavirus; HCV: hepatitis C virus; KSHV: Kaposi sarcoma herpesvirus; HHV8: human herpesvirus 8; MCV: Merkel cell 
polyomavirus.
 Mechanisms of viral oncogenesis
Cancer is the final result of several genetic cellular changes, 
which may be responsible for the alteration in the balance of some 
mechanism such proliferation, programmed cell death (apoptosis) 
and cell transformation. The neoplastic cell transformation may be 
divided into initiation, promotion and progression. Furthermore, there 
is generally a long latent period from the moment of carcinogenic 
exposure to the neoplastic transformation, in which somatic cells are 
capable of proliferating without appropriate control, accumulating 
multiple genetic mutations that ultimately may result in  disease(8).
The oncogenesis mechanisms in humans are commonly 
multifactorial and complex, inasmuch as several factors may act on 
different mechanisms and in different stages of tumoral development. 
Thus, it is difficult to pinpoint which mechanism a carcinogen is 
acting on, although its association with a specific type of cancer has 
been established by epidemiological data.
According to Schulz(32), despite its diversity, human cancers 
exhibit fundamental properties that may aid to grasp the mechanisms 
of viral oncogenesis:
• augmented cell proliferation;
• insufficient apoptosis;
• altered cell and tissue differentiation;
• altered metabolism;
• genomic instability;
• immortalization (growth in spite of replicative senescence);
• invasion of different tissue layers;
• metastasis in local lymph nodes and distant tissues.
Some of them are discussed herein.
The viral infection of a cell may result in the alteration of its 
properties, as it occurs in the so called cellular transformation, which 
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generally includes the loss of growth control, anchorage-independent 
growth, ability to invade extracellular matrix, loss of differentiation 
and immortalization. Transformed cells commonly present 
chromosomal abnormalities, which may result in the integration of 
viral genome into hostage cell chromosomes. 
Cancer cell hyperproliferation is a result of an altered response to 
controlling signals of cellular growth. These cells are hypersensitive to 
growth stimulus signals, frequently becoming independent of them. 
Furthermore, the sensitivity to growth inhibitory signals is diminished 
or even absent.
Therefore, there are two mutational routes by which cellular 
proliferation becomes uncontrolled, which may characterize cancer. 
The first occurs when a “stimulator” gene is hyperactive (oncogene) 
and the second when an “inhibitor” gene is inactive (tumor 
suppressor gene)(32).
The viral genome region that is able to generate a tumor is 
known as oncogene. This gene may be incorporated into a hostage 
cell by the virus, resulting in alteration of its properties(25).
The first group of oncoges discovered by the end of 1970’s 
belonged to the genome of acute transforming retroviruses, 
which cause cancers in birds and mammals. The second group 
of oncogenes consists of hostage proto-oncogenes, which become 
active when the insertion of a slow transforming retrovirus disturbs 
its regulation(23).
Nevertheless, retroviral insertion is only one among several 
mechanisms  capable of prompting cellular pro-oncogenes to act as 
oncogenes. Other mechanisms include chromosomal translocation, 
genetic amplification and punctual mutation. They change the 
regulation and/or function of cellular genes, which are then activated, 
hence becoming oncogenes. Consequently, their proteic products may 
become overexpressed, deregulated, hyperactive or poorly located in 
the cell(32).
Several cellular proto-oncogenes regulate cellular proliferation, 
differentiation and survival also in its normal state. Some of them 
act as extracellular growth factors, others as their receptors and some 
of them as juxtamembrane adaptors or transducers in signaling 
cascades. Kinase proteins are another significant type of proto-
oncogene products(16).
There are a few cases in which only one oncogene is sufficient to 
generate malignity. In fact, only one oncogene provides some aspects 
of malignant phenotype and cooperates with others or with defects in 
tumor suppressor genes in the complete transformation(16).
Whereas oncogenes promote the development of tumors due to 
the increase in its activity or deregulation, the suppressor genes need 
to lose its function so that the tumor occurs.
Retinoblastoma represents a paradigm for tumor suppressor 
genes, inasmuch as the inactive tumor suppressor gene of this 
disease (RB1) codifies a central regulator of cellular cycle, 
predominantly G1S transition, which apart from ensuring the 
accurate mitotic segregation, it affects chromatin structure and 
regulates apoptosis(32).
RB1 product (protein pRB) acts by means of binding and 
control of other proteins, mainly E2F transcriptional factors, which 
have the capacity to activate the required genes for the entrance in 
the S phase cell cycle  and for DNA synthesis. In some cases, it may 
induce apoptosis. pRB is regulated via phosphorylation by cyclin- 
dependent kinases, which are linked with their own regulatory 
subunits(38). 
On the one hand, the loss of pRB function directly implies 
cellular proliferation and differentiation. On the other hand, the loss 
of suppressor genes such as TP53 compromises the cell ability to 
react to damages in the genome, which may occur in viral infections. 
Accordingly, the function loss of this gene allows the survival and 
cellular proliferation with an accumulation of mutations, hence 
promoting cancer(22).
Protein p53 plays a pivotal role in the regulation of several 
signaling pathways that control cellular response to DNA damages 
caused by different agents such as ultraviolet light, ionizing radiation 
and chemical carcinogens. It is a transcriptional regulatory protein 
induced by the response to DNA damage. Furthermore, it may 
lead to the stop of cellular cycle or induce apoptosis in response to 
metabolic depletion, thermal shock, hypoxia, viral oncoproteins and 
activated cellular oncogenes. In these situations, p53 is stabilized, 
it accumulates rapidly, undergoes post-translational modifications 
and it regulates the progression of cellular cycle at checkpoinst so 
that DNA may be repaired. In case the damage persists, the cell is 
eliminated by apoptosis(34).
Apoptosis plays a major role in the regulation of normal cell 
population. The suppression of this process may be a decisive factor in 
cancer development. The inability to respond to DNA damage, either 
with the cell cycle arrest or apoptosis induction, results in one of the 
aspects of cancer cells: genomic instability(28).
This genomic instability may contribute to a rapid selection 
of cellular populations capable of overcoming environmental 
factors that arise during the tumoral progression. Accordingly, the 
genomic instability has been described as a major characteristic 
in tumoral cells(21).
The role of laboratory medicine
Currently, the investigation into tumoral markers is one of the 
fastest growing areas in laboratory medicine(11). Tumoral markers 
are molecules that present biological alterations in cellular functions 
commonly associated with malignity, which may be detected in the 
tumoral tissue, serum, plasma or in other body fluids. These substances 
are generally proteins or glycoproteins, though phospholipids, DNA or 
ribonucleic acid (RNA) may also be directly produced by the tumor or 
in response to tumor presence(33).
Similar to other diagnostic tests, tumoral markers are cancer 
surrogate markers, with potential clinical application in the 
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assessment of risk, early detection, diagnosis, molecular classification, 
prognosis, as well as evaluation of application and response to 
treatment, metastasis and recurrence(35).
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer 
worldwide and the third most common cause of cancer-related, with 
over 500 thousand cases diagnosed annually. The incidence of HCC 
is highly variable, depending on geographic region and exposure to 
risk factors. 70%-90% of patients with HCC present history of chronic 
hepatopathy and cirrhosis, whose main risk factors include infection 
by HBV, HCV, alcoholic hepatic disease and non-alcoholic hepatic 
steatosis. Considered one of the most aggressive forms of cancer, HCC 
generally presents bad prognosis due to late diagnosis, advanced 
staging, mostly untreatable(15).
For the risk population, the active tracking of HCC is 
recommended through abdominal ultrasonography and periodic 
evaluation of tumoral markers. In this specific case, the rise in serum 
alpha-fetoprotein levels (AFP) may be the first indication of malignity, 
which must be investigated through imagery test, including CT scan 
and magnetic resonance imaging, as well as ultrasonography or 
histological exams through biopsy.
Although several HCC tumoral markers are currently under 
investigation, AFP is the only hepatic cancer marker applied in the 
clinical practice. AFP is a glycoprotein 70kD, normally produced 
during gestation, and may be assessed by immunoassays with 
monoclonal and/or polyclonal antibodies. AFP should not be 
considered a diagnostic marker in isolation due to its low sensitivity 
and specificity. Approximately 40% of patients with HCC present 
normal levels of AFP and high levels of it may be observed in patients 
with chronic hepatopathy or cirrhosis, in the absence of HCC and 
in patients with other malignities. The determination of AFP has 
been recently removed from the recommendations endorsed by the 
American Association for the Study of Liver Diseases (AASLD)(7).  
Cervical cancer
Cervical cancer is the main cause of death by gynecological 
cancer worldwide, with high incidence mostly in developing countries. 
High risk HPV (types 16, 18, 45 and 56) are the main agents involved 
in the pathogenesis of cervical cancer(37).
The screening in asymptomatic women through Papanicolaou 
smear allows the diagnosis of treatable pre-invasive lesions, thus 
avoiding the progression to malignity. Nevertheless, in developed 
countries most cases of cervical cancer occur among women that 
did not undergo regular screening. On the other hand, in developing 
countries, the access to these services are not available and most 
women present an advanced stage of the disease, with involvement of 
the bladder, rectum, pelvic nerves and bones(37).
Approximately 85% of the cases are squamous cell cervical 
carcinomas. The other histological types include adenocarcinoma 
(10%-15%) and adenosquamous carcinoma (3%)(37).
The tumoral markers may aid in the approach to cervical cancer 
and several other potential markers  have been researched. The choice 
marker for squamous cell carcinoma is the squamous cell carcinoma 
antigen (SCC), whose serum levels are correlated with staging, tumor 
size, residual presence after treatment, recurrence, disease progression 
and survival. However, it is not sufficiently sensitive or specific to 
screening and diagnostic purposes(36).
SCC is a subfraction of TA-4, an antigen associated with tumors, 
which belongs to serine-protease inhibitors. Studies on molecular 
cloning in genomic regions have revealed the presence of two genes 
that codify SCC in two isoforms. The neutral isoform is present in 
tissue and epithelial cells regardless of malignity, whereas the acidic 
isoform is found exclusively in tumor cells, mainly those located 
in the tumor peripheral area and serum from patients with well 
differentiated squamous cell carcinoma(26).
High levels of SCC are found in the initial diagnosis of 
approximately 60% of patients with cervical cancer. More specifically, 
serum SCC is high in approximately 24%-53% of patients in the initial 
stage and 75%-90% in advanced stages(26).
The carcioembryonic antigen (CEA) and CA125 may be useful in 
patients with cervical adenocarcinoma. 
PErSPECtivES
As it commonly occurs in any branch of medicine and clinical 
research, the development of genomic and proteomic technologies 
have changed the approaches and experimental applications of 
tumor markers. Initiating with genetic and molecular biology 
technologies used in the analysis of the human genome, the recent 
years have been characterized by the growing use of techniques for 
the determination of genomic and proteomic profiles such as the 
following: oligonucleotids and complementary DNA microarrays, 
array-based comparative genomic hybridization (CGH), serial 
analysis of gene expression (SAGE), two-dimensional electrophoresis 
in polyacrylamide gel (2-DPAGE), mass spectrometry with matrix 
assisted laser desorption ionization (MALDI), surface enhanced 
laser  desorption ionization (SELDI) and time of flight (TOF), 
among others(33). These technologies combined with clinical 
interpretation of molecular diagnosis and molecular medicine 
have accelerated advances in information and technology in this 
research area(33). These changes will certainly affect the field of 
tumor markers and their application in the near future, resulting in 
better diagnostic tools, prognosis and cancer treatment. Therefore, 
laboratory medicine will play an increasingly outstanding and 
fundamental role in this area. 
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rESuMo 
Os vírus causadores de câncer são responsáveis por até 20% dos cânceres de etiologia infecciosa, representando um grave problema de 
saúde pública em todo o mundo. Desde a descoberta do primeiro vírus causador de neoplasias em humanos, vários outros têm sido 
associados ao câncer. Recentes avanços nas tecnologias de determinação de perfis genômicos e proteômicos resultaram na descoberta e 
na disponibilização de marcadores tumorais com potencial aplicação no rastreamento, no diagnóstico, no prognóstico e no tratamento 
do câncer, destacando a medicina laboratorial como ferramenta fundamental na prevenção e no manejo dessas enfermidades. 
  
Unitermos: vírus oncogênicos; marcadores de tumor; testes laboratoriais.
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